Skip to main content Help with accessibility Skip to main navigation

Guidelines

Transition of Commissioning Policies

On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.

Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.

NHS Cheshire and Merseyside Commissioning Policies

 

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page.

Documents

Date Added: 27 - Apr - 2022

The Pan Mersey Area Prescribing Committee recommends the prescribing of biological agents (adalimumab, certolizumab, etanercept, golimumab, infliximab, secukinumab and ustekinumab) by specialists only, for inflammatory monoarthritis or oligoarthritis as specified.

MONOARTHRITIS or OLIGOARTHRITIS pathway

Monoarthritis or oligoarthritis, inflammatory: biological agents (South Sefton and Southport and Formby CCGs)

Monoarthritis or oligoarthritis pathway (South Sefton and Southport & Formby CCGs)

Body System: